Oncolys BioPharma Inc.
 

March, 2004 Incorporated Oncolys BioPharma in Tokyo, Japan
May, 2004   First round of financing
August, 2004   Second round of financing
October, 2004   Third round of financing
May 2005 Telomescan was adopted by NEDO's grant in 2005 titled, "Project for R&D on Molecule Imaging Equipment. R&D of Molecule Imaging Equipment for Malignant Tumor Therapy Support."
*NEDO: New Energy and Industrial Technology Development Organization
February 2006 Fourth round of financing
March 2006 Filed an investigational new drug (IND) application for Telomelysin® with U.S. Food and Drug Administration (FDA)
March 2006 Fifth round of financing
June 2006 Concluded a joint development agreement with Sysmex Corporation to develop TelomeScan®
June 2006 Concluded an exclusive license agreement with Yale University, granting Oncolys global exclusive license agreement of the novel anti-HIV agent, FESTINAVIR®
September 2006 Sixth round of financing
October 2006 Seventh round of financing
October 2006 Obtained a patent for Telomelysin® in Japan (Patent No. 3867968)
October 2006 Initiated a phase I clinical trial with Telomelysin® in the US
September 2007 Award by Minister of Education, Culture, Sports, Science and Technology, "The 5th Japan Bio-Venture Award"
November 2007 Opened the Kobe Research Center
March 2008 Signed strategic alliance and license agreement with Medigen Biotechnology Corp. for Telomellysin®
March 2008 Signed strategic alliance and license agreement with Tacere Therapeutics, Inc. for OBP-701(TT-033)
March 2008 Eighth round of financing
March 2008 Filed an investigational new drug (IND) application for FESTINAVIR® Food and Drug Administration (FDA)
May 2008 Initiated a phase Ia clinical trial with FESTINAVIR® in the US
August 2008 Apply to start phase Ib clinical study for FESTINAVIR® with Agence française de sécurité sanitaire des produits de santén (AFSSAPS)
January 2009 Initiated a phase Ib/IIa clinical trial with FESTINAVIR® in the FRANCE
October 2009 Signed an exclusive worldwide licensing agreement of OBP-801 with Astellas Pharma
December 2010 Signed an exclusive worldwide licensing agreement of FESTINAVIR® with Bristol-Myers Squibb
January 2011 Terminated licensing agreement of OBP-701 due to the strategic reason

| HOME |
Copyright (c)2004-2005, Oncolys BioPharma Inc. All rights reserved.